Last reviewed · How we verify
1% lidocaine with sodium bicarbonate
1% lidocaine with sodium bicarbonate, marketed by Montefiore Medical Center, holds a niche position in the local anesthetic market. The key composition patent expiring in 2028 provides a period of exclusivity, enhancing the drug's competitive edge. However, the lack of reported revenue and key trial results poses a significant risk to assessing its commercial viability and therapeutic efficacy.
At a glance
| Generic name | 1% lidocaine with sodium bicarbonate |
|---|---|
| Also known as | Intravesical lidocaine |
| Sponsor | Montefiore Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Bladder Directed vs. Pelvic Floor Therapy in IC/BPS (PHASE2)
- The Effect of Local Anesthesia Techniques on Postoperative Pain After Laser Treatment of Pilonidal Sinus (NA)
- Split Face Study of the Duration of Local Anesthetics - Fourth Arm (PHASE4)
- WALANT Versus Local Anesthesia in Central Venous Catheter Insertion (NA)
- The Effectiveness of Intracuff Dexmedetomidine in Preventing Postoperative Sore Throat Following Prone Surgery (PHASE2)
- Carpal Tunnel Release Under Local Anaesthesia With or Without Distal Median Nerve Block (NA)
- aDjunct bicarbonatE in Local anaesthesIa for CarpAl Tunnel rElease (DELICATE) (NA)
- Evaluate Buffering Local Anesthetic in Inflamed Teeth (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 1% lidocaine with sodium bicarbonate CI brief — competitive landscape report
- 1% lidocaine with sodium bicarbonate updates RSS · CI watch RSS
- Montefiore Medical Center portfolio CI